BioInvent MM candidate on clinical hold

BioInvent International AB (SSE:BINV) sagged SEK0.53 (22%) to SEK1.88 after the company said FDA placed a clinical hold on the company's Phase II study of BI-505 as an add-on therapy in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) with high-dose melphalan. BioInvent said the hold is due to an adverse cardiopulmonary event reported in the trial...